Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA – Get Free Report)’s share price traded down 6.1% during mid-day trading on Tuesday. The stock traded as low as $0.4705 and last traded at $0.4740. Approximately 82,392 shares traded hands during trading, a decline of 31% from the average session volume of 119,966 shares. The stock had previously closed at $0.5050.
Kairos Pharma Price Performance
The stock’s 50-day moving average is $1.10 and its two-hundred day moving average is $2.83. The stock has a market cap of $1.63 million, a P/E ratio of -0.25 and a beta of 1.85.
Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.42) earnings per share (EPS) for the quarter. On average, analysts anticipate that Kairos Pharma, Ltd. will post -2.59 EPS for the current fiscal year.
About Kairos Pharma
Kairos Pharma, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies designed to address immune suppression and treatment resistance within the tumor microenvironment. The company’s research is centered on immuno-oncology approaches intended to improve the body’s ability to recognize and attack cancer cells. Kairos Pharma is developing a pipeline of investigational therapies, including antibody-based and small-molecule programs aimed at biological pathways associated with tumor growth, immune evasion and resistance to existing treatments.
Further Reading
- Five stocks we like better than Kairos Pharma
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
